Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-75 years old, male or female, signed informed consent form~2. Advanced NSCLC diagnosed by pathological or clinical physicians~3. Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1~4. Participants must have ≥ 1 measurable lesion as defined per RECIST v1.1~5. Participants must have no prior systemic chemotherapy for advanced or metastatic NSCLC~6. Life expectancy ≥ 12 weeks~7. Participants must have adequate organ function~8. Male/female is willing to use a highly effective method of birth control~Exclusion Criteria:~1. Diagnosed with NSCLC but with epidermal growth factor receptor (EGFR)-sensitizing mutation or anaplastic lymphoma kinase (ALK) gene translocation~2. Received any approved systemic anticancer therapy within 28 days prior to the initiation of study treatment~3. Received prior treatment with EGFR inhibitors or ALK inhibitors~4. Received prior therapies targeting programmed cell death protein-1 (PD-1) or programmed cell death protein ligand-1 (PD-L1)~5. With history of interstitial lung disease, non-infectious pneumonitis or uncontrolled systemic diseases~6. Clinically significant pericardial effusion~7. Severe infections, active leptomeningeal disease or uncontrolled, untreated brain metastasis~8. Any major surgical procedure ≤ 28 days before randomization~9. Human immunodeficiency virus (HIV) infection~10. Participants with untreated hepatitis B or C virus (HBV/HCV)~11. Active autoimmune diseases or history of autoimmune diseases~12. History of allergic reactions to chemotherapy~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tislelizumab + Platinum + Pemetrexed (Type: EXPERIMENTAL): Tislelizumab 200 milligrams (mg) administered intravenously (IV) once every 3 weeks plus cisplatin 75 mg/m\^2 or carboplatin area under the plasma or serum concentration-time curve (AUC) 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)
- Platinum + Pemetrexed (Type: ACTIVE_COMPARATOR): Cisplatin 75 mg/m\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).